The financials
United Therapeutics Corporation by the numbers
United Therapeutics Corporation (UTHR) reported revenue of $782M in Q1 2026 (quarter ended March 31, 2026), down 1.6% from the same quarter a year earlier. That came with a gross margin of 83% and net income of $275M (35% of revenue). For the full year FY2025, revenue was $3.18B (+11% year on year) and net income $1.33B. Its largest product in 2026-Q1 was Tyvaso DPI at $330M, 42% of the disclosed total, just ahead of Orenitram at 17%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $782M | $794M | −1.6% |
| Gross profit | $648M | $702M | −7.7% |
| Operating income | $326M | $383M | −15% |
| Net income | $275M | $322M | −15% |
| Diluted EPS | $5.82 | $6.63 | −12% |
| Product | Revenue | Share |
|---|---|---|
| Tyvaso DPI | $330M | 42% |
| Orenitram | $136M | 17% |
| Nebulized Tyvaso | $127M | 16% |
| Remodulin | $127M | 16% |
| Unituxin | $54M | 6.9% |
| Product And Service Other | $5.3M | 0.7% |
| Adcirca | $2.9M | 0.4% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $781.5M (-2.3%)
Orenitram grew +12% year on yearAdcirca -52% year on year
Segment Latestquarter on quarteryear on year
- Tyvaso DPI$330.3M$330.3MQoQ -1.8%year on year +9.2%-1.8%+9.2%
- Orenitram$135.6M$135.6MQoQ +3.4%year on year +12%+3.4%+12%
- Nebulized Tyvaso$127.2M$127.2MQoQ -10%year on year -22%-10%-22%
- Remodulin$126.6M$126.6MQoQ +0.56%year on year -8.4%+0.56%-8.4%
- Unituxin$53.6M$53.6MQoQ +12%year on year -7.9%+12%-7.9%
- Product And Service Other$5.3M$5.3MQoQ -23%year on year +6.0%-23%+6.0%
- Adcirca$2.9M$2.9MQoQ -70%year on year -52%-70%-52%
Drug Manufacturers - Specialty & Generic
Ranks #6 of 28 by Smart Score